Clinical Trial

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms. This study aims to examine the sex difference in the efficacy of an NMDA-enhancer (NMDAE) for the treatment of negative symptoms in schizophrenia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-08.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT07122895
Lead Sponsor China Medical University Hospital
Collaborators: National Science and Technology Council, Taiwan
Conditions Schizophrenia
Enrollment 90 participants
Start Date 2025-09-16
Primary Completion 2029-12 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-17